Almac Clinical Technologies Hires New Director in San Francisco Office
October 8, 2007
27 September 2007. Yardley, Pennsylvania. Almac Clinical Technologies announced today the addition of Peter St. Wecker, Ph.D., to the Almac Clinical Technologies management team. Peter will serve as Director of Clinical Project Services supporting Almac’s San Francisco, CA office. With more than twelve years of experience in the pharmaceutical industry, Peter joins the Almac team after spending over five years in various clinical development leadership roles at a major west coast biotechnology company and six years in global clinical program management at a leading international CRO. Peter earned his Ph.D. in Neurophysiology from the University of North Carolina at Chapel Hill and a B.A. in Chemistry from Earlham College.
In recent years, Peter has served in various leadership positions including project management and clinical operations, where he has been responsible for the development, integration and implementation of various clinical technologies including IVRS, EDC, ePRO and CTMS. His experience in both vendor and sponsor roles allows him a keen perspective related to the challenges and key factors associated with the successful use of clinical technology.
Valarie Higgins, Vice President of Clinical Project Services adds
“Peter’s vast experience with the clinical process and his experience working in the biotechnology setting will enable our San Francisco office to continue to set the standard for customer focused high quality services in support of the biotech community. We are pleased to welcome Peter to our team.”
Almac Clinical Technologies is a division of Almac that specializes in interactive technology and service solutions to increase the quality and efficiency of the clinical trial process. Our solutions include Interactive Voice and Web Response Systems (IXRS™) for patient randomization, tracking and clinical supply management, iTrial EDC for electronic case report form data collection, electronic patient reported outcome data collection, and web drug reconciliation.
The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, diagnostic/genomic services, API manufacture, formulation development, clinical trial supply and technology (IVRS/EDC), to commercial-scale manufacture. Almac provides services to over 600 companies including all the world leaders in the pharmaceutical and biotech sectors. The company is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.
Contact: Meghan Adams US: 267-685-4284 / [email protected]